Oncolytics Biotech Inc ONCY

Primary Symbol: T.ONC

Healthcare Biotechnology

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.

TSX:ONC - Post by User

Oncolytics Biotech Inc > Pelareorep + Paclitaxel = ADC/HER2 failed breast cancer

<< Previous

Bullboard Posts

Next >>

Comment by Noteableon Aug 19, 2024 10:14am

154 Views

Post# 36185774

RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE: Pelareorep + Paclitaxel = ADC/HER2 failed breast cancer

All FDA Approved ADC Therapies


Enhertu	Daiichi Sankyo	NSCLC; gastric cancer; breast cancer	2019
Zynlonta	ADC Therapeutics	DLBCL	2021
Blenrep	GlaxoSmithKline	Multiple myeloma	2020
Tivdak	Seagen	Cervical cancer	2021
Trodelvy	Gilead Sciences	Bladder cancer; breast cancer	2020
Elahere	ImmunoGen	Ovarian cancer	2022
Polivy	Roche	DLBCL	2019
Padcev	Astellas	Bladder cancer	2019
Besponsa	Pfizer	ALL	2017
Kadcyla	Roche	Breast cancer	2013
Adcetris	Seagen	NHL; Hodgkin’s lymphoma	2011
Mylotarg	Pfizer	AML	2017 (reinstated)
Zevalin	Aurobindo Pharma	NHL, follicular lymphoma	2002